Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.

@article{Papakostas2008EfficacyOB,
  title={Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.},
  author={G. Papakostas and S. Stahl and A. Krishen and C. A. Seifert and V. Tucker and E. P. Goodale and M. Fava},
  journal={The Journal of clinical psychiatry},
  year={2008},
  volume={69 8},
  pages={
          1287-92
        }
}
  • G. Papakostas, S. Stahl, +4 authors M. Fava
  • Published 2008
  • Medicine, Psychology
  • The Journal of clinical psychiatry
  • OBJECTIVE The goal of this work was to compare the efficacy of the norepinephrine and dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depressive disorder with high levels of anxiety (anxious depression). METHOD Ten double-blind, randomized studies from 1991 through 2006 were combined (N = 2122). Anxious depression was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) anxiety-somatization factor score… CONTINUE READING
    87 Citations
    Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline
    • B. Bandelow, M. Bauer, +4 authors H. Eriksson
    • Psychology, Medicine
    • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
    • 2014
    • 17
    Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
    • 3
    Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study
    • 9
    Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram
    • 30
    Agomelatine in the treatment of major depressive disorder
    • 130

    References

    SHOWING 1-10 OF 42 REFERENCES
    Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    • 127
    Does pretreatment anxiety predict response to either bupropion SR or sertraline?
    • 27
    • Highly Influential
    Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    • 833
    • PDF
    Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline
    • 51
    • Highly Influential
    • PDF